Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia

No abstract is available for this paper.

• Publication year

  2016

• Venue

  CNS Drugs

• Publication date

  2016-06-02

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1007/s40263-016-0350-7PMID 27255405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

  2016cited by this paper
• Re: Review article titled ‘Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia’ (Stevens GL et al. Early Interv Psychiatry 2015 Sep 25. doi: 10.1111/eip.12278)

  2016cited by this paper
• Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3‐month formulation in patients with schizophrenia: A phase‐1, single‐dose, randomized, open‐label study

  2016cited by this paper
• Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice

  2015cited by this paper
• The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia.

  2015cited by this paper
• Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.

  2015cited by this paper
• Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia

  2015cited by this paper
• Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies.

  2015cited by this paper
• Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.

  2015cited by this paper
• Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.

  2015cited by this paper
• Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review

  2015cited by this paper
• Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.

  2015cited by this paper
• Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study.

  2015cited by this paper
• Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.

  2015cited by this paper
• Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With Schizophrenia.

  2015cited by this paper
• Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics

  2015cited by this paper
• Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia

  2015cited by this paper
• A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.

  2015cited by this paper
• Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.

  2015cited by this paper
• Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole.

  2015cited by this paper
• Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.

  2015cited by this paper
• Why are long-acting injectable antipsychotics still underused?

  2015cited by this paper
• A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.

  2014cited by this paper
• Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study

  2014cited by this paper
• Organizational Barriers to Using Long-Acting Injectable Antipsychotics in Practice

  2014cited by this paper
• Long-acting injectable antipsychotics: shall the last be first?

  2014cited by this paper
• Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study

  2014cited by this paper
• Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

  2014cited by this paper
• Long-acting injectable antipsychotics: an underutilized treatment option.

  2014cited by this paper
• Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases

  2014cited by this paper
• The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

  2014cited by this paper
• Attitudinal barriers to prescribing LAI antipsychotics in the outpatient setting: communicating with patients, families, and caregivers.

  2014cited by this paper
• Barriers to Utilizing Long-Acting Injectable Antipsychotic Medications

  2014cited by this paper
• Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia

  2014cited by this paper
• A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections

  2014cited by this paper
• Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics

  2014cited by this paper
• Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia

  2013cited by this paper
• Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.

  2013cited by this paper
• A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part I-patient perspectives.

  2013cited by this paper
• Patients’ and clinicians’ attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis

  2013cited by this paper
• Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?

  2013cited by this paper
• Why Are Canadians Complacent about Long-Acting Injectable Antipsychotic Therapies? Come on, Canada, You Can Do Better!

  2013cited by this paper
• Psychiatrists’ awareness of partial and nonadherence to antipsychotic medication in schizophrenia: results from an Asia–Pacific survey

  2013cited by this paper
• A Qualitative Study of Experiences with and Perceptions regarding Long-Acting Injectable Antipsychotics: Part II—Physician Perspectives

  2013cited by this paper
• Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.

  2013cited by this paper
• Long-Acting Injectable Antipsychotics: Recommendations for Clinicians

  2013cited by this paper
• Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review

  2013cited by this paper
• Long‐acting injectable antipsychotics in early psychosis: a literature review

  2013cited by this paper
• Barriers to utilizing long-acting injectable antipsychotic medications.

  2013cited by this paper
• Long-Acting Injectable Formulations of New-Generation Antipsychotics: A Review from a Clinical Perspective

  2013cited by this paper
• Guidelines sur les antipsychotiques atypiques d’action prolongée (APAPs) dans les premiers épisodes psychotiques

  2013cited by this paper
• The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia

  2013cited by this paper
• Addressing Barriers to Using Long-Acting Injectable Antipsychotics and Appropriately Monitoring Antipsychotic Adverse Effects

  2013cited by this paper
• Non‐adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies

  2013cited by this paper
• Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

  2013cited by this paper
• [Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia].

  2013cited by this paper
• Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection

  2012cited by this paper
• A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.

  2012cited by this paper
• Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study.

  2012cited by this paper
• Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons

  2012cited by this paper
• Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model

  2012cited by this paper
• Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review

  2012cited by this paper
• Rethinking the role of long-acting atypical antipsychotics in the community setting

  2012cited by this paper
• Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia

  2012cited by this paper
• Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial

  2011cited by this paper
• Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

  2011cited by this paper
• Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

  2011cited by this paper
• Psychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia

  2011cited by this paper
• Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis of Second-Generation Antipsychotics versus First-Generation Antipsychotics

  2011cited by this paper
• Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial

  2011cited by this paper
• Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial

  2011cited by this paper
• Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results

  2011cited by this paper
• Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

  2011cited by this paper
• A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

  2011cited by this paper
• Barriers to, and Strategies for, Starting a Long Acting Injection Clinic in a Community Mental Health Center

  2011cited by this paper
• Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

  2011cited by this paper
• A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

  2011cited by this paper
• Long-Term Safety and Tolerability of Open-Label Olanzapine Long-Acting Injection in the Treatment of Schizophrenia: 190-Week Interim Results

  2011cited by this paper
• A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.

  2011cited by this paper
• Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

  2010cited by this paper
• Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.

  2010cited by this paper
• Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists.

  2010cited by this paper
• A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

  2010cited by this paper
• CERP – CENTRES OF EXCELLENCE IN RELAPSE PREVENTION. AN INTERNATIONAL EDUCATIONAL PROGRAMME TO ENHANCE RELAPSE PREVENTION IN SCHIZOPHRENIA

  2010cited by this paper
• Assessment of Adherence Problems in Patients with Serious and Persistent Mental Illness: Recommendations from the Expert Consensus Guidelines

  2010cited by this paper
• Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years

  2010cited by this paper
• The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

  2009cited by this paper
• Historical perspective on antipsychotic long-acting injections

  2009cited by this paper
• Clinical guideline recommendations for antipsychotic long-acting injections

  2009cited by this paper
• The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

  2009cited by this paper
• A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.

  2009cited by this paper
• Comparison of Drug Adherence Rates Among Patients with Seven Different Medical Conditions

  2008cited by this paper
• Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting.

  2008cited by this paper
• Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.

  2008cited by this paper
• An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

  2008cited by this paper
• Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study.

  2007cited by this paper
• Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States

  2007cited by this paper
• The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.

  2007cited by this paper
• The case for long‐acting antipsychotic agents in the post‐CATIE era

  2007cited by this paper
• Long-Acting Formulations of Atypical Antipsychotics

  2007cited by this paper

• Preferences for PrEP Implementation and Engagement in the HIV Pre-Exposure Prophylaxis (PrEP) Care Continuum among Patients Receiving Psychiatric Care in an Ending the HIV Epidemic Priority County.

  2025cites this paper
• An analysis of the clinical application of paliperidone palmitate injection based on real-world

  2025cites this paper
• Clinician differences in attitudes and perceptions on the use of long-acting injectable antipsychotic agents in treating patients with schizophrenia: results from the US DECIDE survey

  2025cites this paper
• Attitudes Driving Regional Differences in Long-Acting Injectable Antipsychotic Utilization for Schizophrenia among Healthcare Professionals, Patients, and Caregivers (ADVANCE): Results from a Multinational Survey Study

  2025cites this paper
• Perceptions and practices of long-acting injectable antipsychotic administration in community pharmacies within Washington state: A qualitative implementation science study.

  2025cites this paper
• Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report.

  2025cites this paper
• Clinical Outcomes in Patients with Schizophrenia Treated with Long-Acting Injectable vs. Oral Antipsychotics: A Naturalistic Study

  2025cites this paper
• Preparation, characterisation, and testing of reservoir-based implantable devices loaded with tizanidine and lidocaine

  2025cites this paper
• A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial

  2024cites this paper
• Schizophrenic patient’s preference for long-acting injectable antipsychotics in Saudi Arabia

  2024cites this paper
• Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses

  2024cites this paper
• Psychopharmacologic Laziness

  2024cites this paper
• What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review

  2023cites this paper
• Time‐to‐therapy discontinuation in patients newly diagnosed with schizophrenia initiated on long‐acting injectable versus oral dopamine receptor blocking agents

  2023cites this paper
• Short communication: Prevalence of long-acting injectable antipsychotic use in Canadian early intervention services for psychosis.

  2023cites this paper
• Solid implantable devices for sustained drug delivery.

  2023cites this paper
• Prescription of Long-Acting Injectable Antipsychotic Medications Among Outpatient Mental Health Care Service Providers.

  2023cites this paper
• Is preventing the second psychotic episode a disease-modifying strategy for schizophrenia?

  2023cites this paper
• Systematic review of community pharmacist administration of long-acting injectable antipsychotic medications.

  2022cites this paper
• Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey

  2022cites this paper
• Barriers and Supports in eHealth Implementation among People with Chronic Cardiovascular Ailments: Integrative Review

  2022cites this paper
• Long-Acting Injectable Antipsychotics (LAIs) Prescribing Trends during the COVID-19 Pandemic in Romania

  2022cites this paper
• 3D-printed implantable devices with biodegradable rate-controlling membrane for sustained delivery of hydrophobic drugs

  2022cites this paper
• Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland

  2022cites this paper
• Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians

  2022cites this paper
• Disruptions in Care for Medicare Beneficiaries With Severe Mental Illness During the COVID-19 Pandemic

  2022cites this paper
• Mirror image study (10 years of follow-up and 10 of standard pre-treatment) of psychiatric hospitalizations of patients with severe schizophrenia treated in a community-based, case-managed programme.

  2022cites this paper
• Antipsychotic prescribing patterns in Australia: a retrospective analysis

  2022cites this paper
• One-Month versus Three-Month Formulation of Paliperidone Palmitate Treatment in Psychotic Disorders: Patients’, Relatives’, and Mental Health Professionals’ Perspectives

  2022cites this paper
• Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia

  2022cites this paper
• Barriers to Long-acting Injectable Antipsychotic Adherence During the COVID-19 Pandemic: Observations From One Site

  2022cites this paper
• Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study

  2022cites this paper
• Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners

  2022cites this paper
• Attitudes and Willingness to Accept Long-Acting Injections for Patients With Schizophrenia in Beijing: A Cross-Sectional Investigation Based on Samples From the Communities

  2021cites this paper
• Prescribing pattern of antipsychotic medication for first-episode psychosis: a retrospective cohort study

  2021cites this paper
• Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate

  2021cites this paper
• Predictors of discontinuation and hospitalization during long-acting injectable antipsychotic treatment in patients with schizophrenia spectrum disorder.

  2021cites this paper
• The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study

  2021cites this paper
• Current and emerging long-acting antipsychotics for the treatment of schizophrenia

  2021cites this paper
• Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis

  2021cites this paper
• Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice

  2021cites this paper
• Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia

  2021cites this paper
• A Program to Increase the Appropriate Use of Long-Acting Injectable Antipsychotic Medications in Community Settings.

  2021cites this paper
• Schizophrenia population health management: perspectives of and lessons learned from population health decision makers

  2021cites this paper
• The Willingness of Community Psychiatric Management Physicians to Preferentially Recommend Long-Acting Injections in Beijing

  2021cites this paper
• Real-World Utilization Patterns of Long-Acting Injectable Antipsychotics in Canada: A Retrospective Study

  2021cites this paper
• Assessing Outcomes Between Risperidone Microspheres and Paliperidone Palmitate Long-Acting Injectable Antipsychotics Among Veterans.

  2021cites this paper
• Olanzapine Pamoate Use for Schizophrenia: Retrospective Records Based Study from a Tertiary Care Hospital

  2020cites this paper
• NDT_A_233537 2063..2072

  2020cites this paper
• Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability

  2020cites this paper
• Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire

  2020cites this paper
• PPA_A_251812 1093..1102

  2020cites this paper
• Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study

  2020cites this paper
• An integrative review on facilitators and barriers in delivering and managing injectable therapies in chronic conditions: A part of the ACNAP project ‘injectable medicines among patients with cardiovascular conditions’

  2020cites this paper
• Long‐acting antipsychotic medication as first‐line treatment of first‐episode psychosis with comorbid substance use disorder

  2020cites this paper
• Persistent Barriers to the Use of Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia.

  2020influential citation
• The effectiveness of long‐acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia

  2020cites this paper
• Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study

  2019cites this paper
• Examining patient outcomes of receiving long-acting injectable antipsychotics.

  2019cites this paper
• Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology

  2019cites this paper
• A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics

  2019cites this paper
• Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics

  2019cites this paper
• Mirror image study (10 years of follow-up and 10 of standard pre-treatment) of psychiatric hospitalizations of patients with severe schizophrenia treated in a community-based, case-managed programme.

  2019cites this paper
• Use of palmitate of paliperidone 1-monthly in patients <40 years old: Results of real clinical practice

  2019cites this paper
• Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

  2019cites this paper
• Prescription Pattern of Long Acting Haloperidol in a Tertiary Psychiatric Institution in South India: Ten - Year Retrospective Records Study

  2019cites this paper
• Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics

  2018cites this paper
• Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1

  2018cites this paper
• Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study

  2018cites this paper
• An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study)

  2018cites this paper
• Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies

  2018cites this paper
• Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents

  2018cites this paper
• Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study

  2018cites this paper
• Simulated long‐term outcomes of early use of long‐acting injectable antipsychotics in early schizophrenia

  2018cites this paper
• Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial

  2018cites this paper
• The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia

  2018cites this paper
• The Use of Long-Acting Injectable Antipsychotics in Schizophrenia

  2017cites this paper
• Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder.

  2017cites this paper
• Barriers to the use of long-acting injectable antipsychotics in schizophrenia may be overcome by implementing a variety of strategies

  2016cites this paper
• Barriers to the use of long-acting injectable antipsychotics in schizophrenia may be overcome by implementing a variety of strategies

  2016influential citation
• Journal of Medicine and Health Studies

  year unknowncites this paper